Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy

被引：2

作者：

Sieghart, Daniela ^{[1
]}

Hana, Claudia A. ^{[1
]}

Durrschmid, Caroline ^{[1
]}

Heinz, Leonhard X. ^{[1
]}

Haslacher, Helmuth ^{[2
]}

Zlesak, Markus ^{[1
]}

Piccini, Giulia ^{[3
]}

Manenti, Alessandro ^{[3
]}

Montomoli, Emanuele ^{[3
,8
]}

Jorda, Anselm ^{[4
]}

Fedrizzi, Clemens ^{[4
]}

Hasenoehrl, Timothy ^{[5
]}

Zdravkovic, Andrej ^{[5
]}

Anderle, Karolina ^{[4
]}

Wiedermann, Ursula ^{[6
]}

Drapalik, Susanne ^{[7
]}

Steinbrecher, Helmut ^{[7
]}

Bergmann, Felix ^{[4
]}

Firbas, Christa ^{[5
]}

Jordakieva, Galateja ^{[5
]}

Wagner, Barbara ^{[5
]}

Leonardi, Margherita ^{[3
]}

Pierleoni, Giulio ^{[3
]}

Ballini, Matilde ^{[3
]}

Benincasa, Linda ^{[3
]}

Marchi, Serena ^{[8
]}

Trombetta, Claudia ^{[8
]}

Perkmann, Thomas ^{[2
]}

Crevenna, Richard ^{[5
]}

Zeitlinger, Markus ^{[4
]}

Bonelli, Michael ^{[1
]}

Aletaha, Daniel ^{[1
]}

Radner, Helga ^{[1
]}

机构：

[1] Med Univ Vienna, Dept Internal Med 3, Div Rheumatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria

[2] Med Univ Vienna, Dept Lab Med, Vienna, Austria

[3] Vismederi Srl, Siena, Italy

[4] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria

[5] Med Univ Vienna, Dept Phys Med Rehabil & Occupat Med, Vienna, Austria

[6] Med Univ Vienna, Inst Spec Prophylaxis & Trop Med, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria

[7] Arbeiter Samariter Bund Wien, Vienna, Austria

[8] Univ Siena, Dept Mol & Dev Med, Siena, Italy

来源：

JOURNAL OF CLINICAL VIROLOGY | 2024年 / 173卷

关键词：

COVID-19; Vaccination; Immunogenicity; Immune response; Neutralizing antibodies; Population -based study; ANTIBODY;

D O I：

10.1016/j.jcv.2024.105661

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Background: Various SARS-CoV-2 variants of concerns (VOCs) characterized by higher transmissibility and immune evasion have emerged. Despite reduced vaccine efficacy against VOCs, currently available vaccines provide protection. Population -based evidence on the humoral immune response after booster vaccination is crucial to guide future vaccination strategies and in preparation for imminent COVID-19 waves. Methods: This multicenter, population -based cohort study included 4697 individuals >= 18 years of age who received a booster vaccination. Antibody levels against SARS-CoV-2 receptor binding domain (RBD) and neutralizing antibodies against wild -type (WT) virus and Omicron variants were assessed at baseline (day of booster vaccination) and after four weeks. Safety was evaluated daily within the first week using a participantcompleted electronic diary. Antibody levels were compared across different vaccination strategies, taking into account individual host factors. Results: Our main model including 3838 participants revealed that individuals who received a booster with mRNA-1273 compared to BNT162b2 vaccine had a significantly higher increase (95 %CI) in anti-RBD-antibody levels (37,707 BAU/mL [34,575 -40,839] vs. 27,176 BAU/mL [26,265 -28,087]), and of neutralization levels against WT (1,681 [1490 -1872] vs. 1141 [1004 -1278] and Omicron variant (422 [369 -474] vs. 329 [284 -374]). Neutralizing antibody titres highly correlated with anti-RBD antibodies, with neutralizing capacity 4.4 fold higher against WT compared to Omicron. No differences in safety were found between the two booster vaccines. Conclusion: Our study underlines the superiority of a booster vaccination with mRNA-1273, independent of the primary vaccination and therefore provides guidance on the vaccination strategy.

引用

页数：8

共 25 条

[11] Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial [J].

Gilbert, Peter B. ;

Montefiori, David C. ;

McDermott, Adrian ;

Fong, Youyi ;

Benkeser, David ;

Deng, Weiping ;

Zhou, Honghong ;

Houchens, Christopher R. ;

Martins, Karen ;

Jayashankar, Lakshmi ;

Castellino, Flora ;

Flach, Britta ;

Lin, Bob C. ;

O'Connell, Sarah ;

McDanal, Charlene ;

Eaton, Amanda ;

Sarzotti-Kelsoe, Marcella ;

Lu, Yiwen ;

Yu, Chenchen ;

Borate, Bhavesh ;

van der Laan, Lars W. P. ;

Hejazi, Nima ;

Huynh, Chuong ;

Miller, Jacqueline ;

El Sahly, Hana M. ;

Baden, Lindsey R. ;

Baron, Mira ;

De la Cruz, Luis ;

Gay, Cynthia ;

Kalams, Spyros ;

Kelley, Colleen F. ;

Andrasik, Michele P. ;

Kublin, James G. ;

Corey, Lawrence ;

Neuzil, Kathleen M. ;

Carpp, Lindsay N. ;

Pajon, Rolando ;

Follmann, Dean ;

Donis, Ruben O. ;

Koup, Richard A. .

SCIENCE, 2022, 375 (6576) :43-+

[12] Usage Data and Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-Based MedUni Wien Biobank [J].

Haslacher, Helmuth ;

Gerner, Marlene ;

Hofer, Philipp ;

Jurkowitsch, Andreas ;

Hainfellner, Johannes ;

Kain, Renate ;

Wagner, Oswald F. ;

Perkmann, Thomas .

BIOPRESERVATION AND BIOBANKING, 2018, 16 (06) :477-482

[13] Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation [J].

Higgins, Victoria ;

Fabros, Anselmo ;

Kulasingam, Vathany .

JOURNAL OF CLINICAL MICROBIOLOGY, 2021, 59 (04)

[14] Immunogenicity and reactogenicity of heterologous and homologous mRNA-1273 and BNT162b2 vaccination: A multicenter non-inferiority randomized trial [J].

Janssen, Cecile ;

Cachanado, Marine ;

Ninove, Laetitia ;

Lachatre, Marie ;

Michon, Jocelyn ;

Epaulard, Olivier ;

Maakaroun-Vermesse, Zoha ;

Chidiac, Christian ;

Laviolle, Bruno ;

Aumaitre, Hugues ;

Assaf, Ady ;

Lacombe, Karine ;

Schmidt-Mutter, Catherine ;

Botelho-Nevers, Elisabeth ;

Briere, Magali ;

Boisson, Thomas ;

Loubet, Paul ;

Bienvenu, Boris ;

Bouchaud, Olivier ;

Touati, Amel ;

Pereira, Christine ;

Rousseau, Alexandra ;

Berard, Laurence ;

Montil, Melissa ;

de Lamballerie, Xavier ;

Simon, Tabassome ;

Launay, Odile .

ECLINICALMEDICINE, 2022, 48

[15] Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study [J].

Jara, Alejandro ;

Undurraga, Eduardo A. ;

Zubizarreta, Jose R. ;

Gonzalez, Cecilia ;

Pizarro, Alejandra ;

Acevedo, Johanna ;

Leo, Katherinne ;

Paredes, Fabio ;

Bralic, Tomas ;

Vergara, Veronica ;

Mosso, Marcelo ;

Leon, Francisco ;

Parot, Ignacio ;

Leighton, Paulina ;

Suarez, Pamela ;

Carlos Rios, Juan ;

Garcia-Escorza, Heriberto ;

Araos, Rafael .

LANCET GLOBAL HEALTH, 2022, 10 (06) :E798-E806

[16] Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection [J].

Khoury, David S. ;

Cromer, Deborah ;

Reynaldi, Arnold ;

Schlub, Timothy E. ;

Wheatley, Adam K. ;

Juno, Jennifer A. ;

Subbarao, Kanta ;

Kent, Stephen J. ;

Triccas, James A. ;

Davenport, Miles P. .

NATURE MEDICINE, 2021, 27 (07) :1205-+

[17] Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples [J].

Manenti, Alessandro ;

Maggetti, Marta ;

Casa, Elisa ;

Martinuzzi, Donata ;

Torelli, Alessandro ;

Trombetta, Claudia M. ;

Marchi, Serena ;

Montomoli, Emanuele .

JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (10) :2096-2104

[18] Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose [J].

Mangia, Alessandra ;

Serra, Nicola ;

Cocomazzi, Giovanna ;

Giambra, Vincenzo ;

Antinucci, Stefano ;

Maiorana, Alberto ;

Giuliani, Francesco ;

Montomoli, Emanuele ;

Cantaloni, Paolo ;

Manenti, Alessandro ;

Piazzolla, Valeria .

FRONTIERS IN PUBLIC HEALTH, 2022, 10

[19] Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine [J].

Mizrahi, Barak ;

Lotan, Roni ;

Kalkstein, Nir ;

Peretz, Asaf ;

Perez, Galit ;

Ben-Tov, Amir ;

Chodick, Gabriel ;

Gazit, Sivan ;

Patalon, Tal .

NATURE COMMUNICATIONS, 2021, 12 (01)

[20] Comparison of SARS-CoV-2 Antibody Response by Age Among Recipients of the BNT162b2 vs the mRNA-1273 Vaccine [J].

Richards, Nathan E. ;

Keshavarz, Behnam ;

Workman, Lisa J. ;

Nelson, Michael R. ;

Platts-Mills, Thomas A. E. ;

Wilson, Jeffrey M. .

JAMA NETWORK OPEN, 2021, 4 (09)

← 1 2 3 →